VolitionRx Reports Significant Clinical and Commercial Progress Across Cancer and Sepsis Detection Platforms
February 25th, 2026 2:12 PM
By: Newsworthy Staff
VolitionRx Ltd. has announced substantial advancements in its epigenetics-based diagnostic platforms, including new cancer detection methods with a $23 billion market opportunity, progress toward routine clinical use of its lung cancer assay in France by 2026, and inclusion in a major government-backed sepsis detection program.
VolitionRx Ltd. has provided a comprehensive update detailing significant clinical and commercial progress across its key epigenetics platforms, highlighting developments in cancer detection, sepsis monitoring, and veterinary diagnostics. The company submitted a manuscript for peer review featuring both a new method called Capture-Seq and new biomarkers for cancer detection, estimating this represents an annualized total addressable market opportunity of approximately $23 billion. This advancement underscores the potential for more accessible and cost-effective cancer screening technologies.
Commercialization efforts for the Nu.Q Cancer assay in lung cancer are advancing, with the company reporting that reimbursement submission in France remains on track. Routine clinical use of the assay is expected by the fourth quarter of 2026, marking a critical step toward integrating this diagnostic tool into standard healthcare protocols. The progress in France demonstrates the growing international acceptance of Volition's epigenetic approaches to disease detection.
In parallel, Volition confirmed the inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France, aimed at the early detection of sepsis. The company also highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting its CE-marked availability across Europe. These developments emphasize the expanding applications of Volition's technology beyond oncology into other life-threatening conditions where early intervention is crucial.
The company reported breakthrough veterinary results demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay. Publication of the feline study is expected to unlock a $5 million contractual milestone payment, illustrating the commercial viability of its veterinary diagnostics. Volition confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and anticipates announcing additional licensing agreements during 2026, signaling growing industry interest in its epigenetic platforms. For more information about the company's developments, visit https://www.Volition.com.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
